Soleno Therapeutics Amends Bylaws, Tightening Shareholder Proposal Rules and Adding Forum Selection

summarizeSummary

Soleno Therapeutics Inc. amended its bylaws to update advance notice provisions for shareholder proposals and nominations, and to include a forum selection clause, which are common corporate governance enhancements.

check_boxKey Events

• Bylaw Amendments Approved

  The Board of Directors approved and adopted Amended and Restated Bylaws, effective March 16, 2026.

• Stricter Shareholder Proposal Rules

  The amendments update advance notice provisions, making it more stringent for stockholders to propose business or nominate directors at annual meetings.

• Exclusive Forum Selection

  A new provision designates the Delaware Court of Chancery as the exclusive forum for certain corporate litigation and federal district courts for Securities Act claims, centralizing legal disputes.

auto_awesomeAnalysis

Soleno Therapeutics Inc. has amended its bylaws to update advance notice provisions for stockholder proposals and director nominations, and to include a forum selection clause. These changes are generally considered defensive corporate governance measures. The stricter advance notice requirements can make it more challenging for activist shareholders to nominate directors or propose business, while the forum selection clause aims to centralize corporate litigation in Delaware courts and federal courts for Securities Act claims. Implementing such defensive measures while the company's stock is trading near its 52-week low could be seen as an effort by the board to protect itself from potential activist pressure, which may be viewed with a slightly negative sentiment from a shareholder rights perspective.